Search
for
Sort by
Research 31–60 of 1000+
- Clinical Case Notes. Castleman's disease of the lacrimal gland
- Arzneimitteltherapie der Alopezien
- Antiandrogens and Androgen Inhibitors
- LOP14
- LOP14
- 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia
- Oral Presentation Abstracts
- Hypertrichosis lanuginosa acquisita following cytotoxic chemotherapy
- Impact of estrogens in males and androgens in females
- Questions and Answers
- Screening: seeking a balance
- Actualités du SOPK
- Treatment options for alopecia: an update, looking to the future
- Oral contraceptives and risk of breast cancer in women aged 20–54 years
- Aromatase inhibitor therapy and hair loss among breast cancer survivors
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
- The Black identity, hair product use, and breast cancer scale
- Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
- Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Next-Gen Therapeutics for Skin Cancer: Nutraceuticals
- Relationship Between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
- Hair regrowth in endocrine therapy alopecia with dutasteride treatment in woman with estrogen positive breast cancer
- Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
- Breast cancer in a transgender man
- Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis
- Miscellaneous Exogenous Hormones and Breast Diseases: A Matter of Concern for the Gynecologist
- Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
- Wedelolactone inhibits breast cancer-induced osteoclastogenesis by decreasing Akt/mTOR signaling